Edition:
United States

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.81USD
12:29pm EST
Change (% chg)

$-0.00 (-0.01%)
Prev Close
$0.81
Open
$0.82
Day's High
$0.82
Day's Low
$0.80
Volume
11,446
Avg. Vol
182,102
52-wk High
$5.25
52-wk Low
$0.78

Chart for

About

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being... (more)

Overall

Beta: 0.86
Market Cap(Mil.): $17.68
Shares Outstanding(Mil.): 21.60
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 8.12 16.04
EPS (TTM): -- -- --
ROI: -- -6.42 34.69
ROE: -- -4.22 15.46

BRIEF-Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14

* Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing Source text: (http://bit.ly/2hydYIN) Further company coverage:

Nov 16 2017

BRIEF-Delmar Pharmaceuticals names Saiid Zarrabian interim CEO

* Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer

Nov 07 2017

BRIEF-DelMar Pharmaceuticals CEO Jeffrey​ Bacha buys 10,000 shares of co's common stock on Oct 6

* DelMar Pharmaceuticals Inc CEO Jeffrey​ Bacha reports open market puchase of 10,000 shares of co's common stock on Oct 6 - SEC filing Source text: (http://bit.ly/2kDnPBr) Further company coverage:

Oct 10 2017

BRIEF-DelMar Pharmaceuticals announces $10 million registered direct offering

* Announces $10 million registered direct offering priced at-the-market

Sep 20 2017

BRIEF-Delmar Pharmaceuticals receives IND allowance from FDA

* Delmar Pharmaceuticals receives IND allowance from FDA to initiate clinical trials of VAL-083 for the treatment of ovarian cancer Source text for Eikon: Further company coverage:

Sep 18 2017

BRIEF-Delmar Pharmaceuticals initiates phase 2 clinical trial

* Delmar Pharmaceuticals initiates phase 2 clinical trial in newly diagnosed MGMT-unmethylated glioblastoma multiforme

Sep 11 2017

BRIEF-Delmar Pharmaceuticals HGRAC approves application to initiate phase 2 of VAL-083

* Delmar Pharmaceuticals receives approval from China's Human Genetic Resources Administration to initiate phase 2 clinical trial in newly diagnosed GBM

Jul 24 2017

BRIEF-Delmar Pharmaceuticals reports completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory GBM

* Delmar Pharmaceuticals announces completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory gbm

Jul 18 2017

BRIEF-Delmar Pharmaceuticals appoints Saiid Zarrabian to board

* Delmar Pharmaceuticals appoints Saiid Zarrabian to the board of directors and names Erich Mohr as chairman

Jul 11 2017

BRIEF-DelMar Pharmaceuticals receives institutional review board approval for pivotal phase 3 clinical trial of VAL-083 in refractory GBM

* DelMar Pharmaceuticals receives institutional review board approval for pivotal phase 3 clinical trial of VAL-083 in refractory GBM

Jun 22 2017

Competitors

Earnings vs. Estimates